By 2030, the rapidly growing immunotherapy industry is set to reach $277.1 billion. While this growth is good news for cancer patients benefiting from these treatment advances, it has started to pose a problem for some oncologists. There are clinicians who find that the number of technological advances being made these days are making it more difficult to keep up with the times.
Current research is focusing on resolving the issue of immunotherapy resistance, which can cause complications for many cancer patients. Other studies are looking at the impact of combination treatment methods that can include immune checkpoint inhibitors, radiation therapy, and targeted therapy.
From a non-clinical perspective, the continued growth in the immunotherapy sector is a positive sign. Currently, this modality is only a viable treatment option for certain types of cancer, making chemotherapy still the more commonly used treatment option. Many professionals are optimistic that additional research and further advances will help immunotherapy soon become the go-to treatment modality for many more types of cancer.
With large amounts of funding for immunotherapy research, insurers will need to be prepared to determine coverage for this cancer treatment. While insurers might not often encounter coverage issues related to immunotherapy, they will need to set a new standard so they can readily respond when this treatment eventually becomes more commonplace.
Another way that insurers can prepare for this surge of claims is by establishing a stronger provider network to support members undergoing cancer treatment. This move will better support and retain existing members who require such specialized medical care. No matter how much assistance your company needs setting up a solid provider network, TOG Network Solutions can help. Reach out for a consultation today.